8-K: Clene Reports Q3 2025 Results, Eyes ALS NDA in Q1 2026

Clene Inc. announced its third quarter 2025 financial results and provided updates on its CNM-Au8 programs for ALS, MS, and PD, including plans for an ALS NDA submission in Q1 2026.

Summary

• Clene reported a net loss of $8.8 million, or $0.85 per share, for the quarter ended September 30, 2025, compared to a net loss of $8.0 million, or $1.22 per share, for the same period in 2024.
• Cash and cash equivalents totaled $7.9 million as of September 30, 2025, a decrease from $12.2 million as of December 31, 2024.
• The company's cash runway is extended into the second quarter of 2026, including $1.2 million additionally raised following the third quarter close.
• Clene plans to submit a New Drug Application (NDA) for CNM-Au8 in ALS in the first quarter of 2026 under an accelerated approval pathway, following further biomarker data analyses and FDA feedback.
• The first patient dosing in the confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 is expected in the first half of 2026.
• The FDA advised Clene to request a Type C meeting to review these further ALS biomarker data analyses, which is expected in Q1 2026.
• In September 2025, Clene held a Type B end-of-Phase 2 meeting with the FDA for its MS program, where the FDA expressed openness to considering cognition as a primary endpoint for the planned Phase 3 study.
• New preclinical data for CNM-Au8 in Parkinson's Disease, announced in September 2025, showed improved key measures of cellular health, supporting continued development.
• Research and development expenses decreased to $3.5 million for Q3 2025 from $4.5 million for Q3 2024, primarily due to cost-saving initiatives and conclusion of clinical programs.
• General and administrative expenses decreased to $2.2 million for Q3 2025 from $3.4 million for Q3 2024, mainly due to reduced legal fees, public/investor relations, and personnel expenses.
• Total other expense increased significantly to $3.1 million for Q3 2025 from $0.2 million for Q3 2024, primarily due to losses from changes in fair value of common stock warrant liabilities and derivative liabilities.

Sentiment

Score: 6

Explanation: While financial results show increased net loss and decreased cash, the operational progress towards an ALS NDA submission and positive FDA interactions for MS and PD preclinical data provide a moderately positive outlook for future potential, despite ongoing cash burn and reliance on future funding.

Positives

• Progress towards NDA submission for CNM-Au8 in ALS under an accelerated approval pathway, targeting Q1 2026.
• FDA openness to considering cognition as a primary endpoint for the planned Phase 3 MS study, indicating flexibility in regulatory approach.
• Positive new preclinical data for CNM-Au8 in Parkinson's Disease, showing improved cellular health and supporting continued development.
• Reduced Research and Development expenses by $1.0 million year-over-year due to cost-saving initiatives and conclusion of various clinical programs.
• Reduced General and Administrative expenses by $1.2 million year-over-year due to decreases in legal fees, public and investor relations expenses, and personnel expenses.
• Cash runway extended into the second quarter of 2026, including $1.2 million raised subsequent to the third quarter close.

Negatives

• Net loss increased to $8.8 million in Q3 2025 from $8.0 million in Q3 2024.
• Cash and cash equivalents decreased to $7.9 million as of September 30, 2025, from $12.2 million as of December 31, 2024.
• Total other expense significantly increased to $3.1 million in Q3 2025 from $0.2 million in Q3 2024, primarily due to losses from changes in fair value of common stock warrant liabilities and derivative liabilities.
• The company has a limited operating history and continues to rely on obtaining additional funding for operations and to complete the development and commercialization of its drug candidates.

Risks

• General market conditions may impact the company's operations and financial performance.
• Clinical trials may not demonstrate the efficacy and safety of drug candidates to the satisfaction of regulatory authorities, or may not otherwise produce positive results, leading to additional costs or delays.
• Clinical results for drug candidates may not support further development or marketing approval.
• Actions of regulatory agencies may affect the initiation, timing, and progress of clinical trials and marketing approval.
• The company's ability to achieve commercial success for its drug candidates, if approved, is uncertain.
• The company's limited operating history and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates pose significant risks.

Future Outlook

Clene anticipates completing ALS biomarker data analyses shortly, which could support an NDA filing in Q1 2026 under an accelerated approval pathway. The company also expects to dose the first patient in the confirmatory Phase 3 RESTORE-ALS trial in the first half of 2026. Cash and cash equivalents, including recent capital raised, are expected to fund operations into the second quarter of 2026.

Management Comments

• "The Company anticipates completing these data analyses shortly which could support the filing of an NDA using the accelerated approval pathway."

Industry Context

Clene operates in the highly competitive and capital-intensive biopharmaceutical sector, specifically targeting neurodegenerative diseases like ALS, MS, and PD. The focus on accelerated approval pathways and biomarker-driven strategies for ALS aligns with broader industry trends seeking faster drug development for severe, unmet medical needs. The FDA's openness to alternative endpoints like cognition for MS also reflects an evolving regulatory landscape that acknowledges the multifaceted nature of these diseases beyond traditional disability scales.

Stakeholder Impact

• Shareholders: Potential for significant value creation if NDA for ALS is approved and clinical trials progress positively, but also risk of dilution from future capital raises and ongoing losses.
• Patients (ALS, MS, PD): Hope for new treatment options if CNM-Au8 proves effective and gains regulatory approval.
• Employees: Continued employment and potential growth opportunities tied to successful drug development and commercialization.
• Creditors: Exposure to the company's financial health and ability to secure future funding.

Next Steps

• Complete analyses of ALS biomarker data shortly.
• Request a Type C meeting with the FDA to review ALS biomarker data analyses (expected Q1 2026).
• Submit a New Drug Application (NDA) for CNM-Au8 in ALS under an accelerated approval pathway (planned Q1 2026).
• Dose the first patient in the confirmatory Phase 3 RESTORE-ALS trial of CNM-Au8 (expected H1 2026).
• Continue development of CNM-Au8 as a treatment for Parkinson's Disease.

Key Dates

Recommendation

The company is making tangible progress towards a potential accelerated approval pathway for its ALS drug candidate, CNM-Au8, with clear timelines for NDA submission and a confirmatory Phase 3 trial. Positive interactions with the FDA regarding MS endpoints and promising preclinical data for PD add to the long-term potential. However, the increased net loss, declining cash reserves, and continued reliance on future capital raises present financial risks. The stock is a 'hold' as the significant clinical milestones could drive future value, but the financial burn rate and regulatory uncertainties warrant caution.

Keywords

Clene Inc., CLNN, biopharmaceutical, neurodegenerative diseases, ALS, amyotrophic lateral sclerosis, MS, multiple sclerosis, Parkinson's Disease, PD, CNM-Au8, FDA, NDA, accelerated approval, Phase 3 trial, RESTORE-ALS, VISIONARY-MS, REPAIR-MS, Q3 2025 financial results, biomarker data, cash runway, mitochondrial health, NAD pathway